Close Menu

NEW YORK — Anpac Bio-Medical Science on Thursday filed with the US Securities and Exchange Commission for a $21.7 million initial public offering on the Nasdaq.

WestPark Capital is acting as the offering's sole bookrunner. The firm has not priced its shares or said how many shares it plans to offer yet. It said that it plans to trade its shares on the Nasdaq Global Market under ticker symbol "ANPC".

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.